# reload+after+2024-01-21 11:36:05.208601
address1§Sussex Innovation Centre
address2§Unit 36 Science Park Square Falmer
city§Brighton
zip§BN1 9SB
country§United Kingdom
phone§44 1273 704440
website§https://www.destinypharma.com
industry§Biotechnology
industryKey§biotechnology
industryDisp§Biotechnology
sector§Healthcare
sectorKey§healthcare
sectorDisp§Healthcare
longBusinessSummary§Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of novel medicines to prevent serious infections in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase II clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in preclinical stage for the treatment of skin infections of antibiotic resistant bacteria, as well as superficial skin infections of antibiotic resistant bacteria. It also develops SPOR-COV, biotherapeutic product, which is in preclinical stage for the prevention of COVID-19 and other viral respiratory infections; and XF Drugs Research/Biofilms that is in preclinical stage for the treatment of antibiotic resistant biofilm and bacterial aggregate associated infections. In addition, the company is involved in the development of XF drugs for the treatment of respiratory, dermal, oral and ocular infections. Destiny Pharma plc has collaboration agreements with China Medical System Holdings Limited; SporeGen Limited; Sebela Pharmaceuticals; the University of Southampton; Aston University; the University of Sheffield; National Biofilms Innovation Centre; National Institute of Allergy and Infectious Diseases; Cystic Fibrosis Foundation; Cardiff University; and Tianjin Medical University. The company was incorporated in 1996 and is based in Brighton, the United Kingdom.
fullTimeEmployees§24
companyOfficers§[{'maxAge': 1, 'name': 'Dr. William Guy Love', 'age': 60, 'title': 'Founder, Chief Scientific Officer & Director', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 265000, 'exercisedValue': 0, 'unexercisedValue': 188419}, {'maxAge': 1, 'name': 'Mr. Shaun  Claydon ACA', 'age': 54, 'title': 'CFO, Company Secretary & Director', 'yearBorn': 1969, 'fiscalYear': 2022, 'totalPay': 286000, 'exercisedValue': 0, 'unexercisedValue': 144375}, {'maxAge': 1, 'name': 'Dr. Debra  Barker M.D., MSc.', 'age': 61, 'title': 'Interim CMO & Senior Independent Director', 'yearBorn': 1962, 'fiscalYear': 2022, 'totalPay': 41000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Christopher John Tovey BSc', 'age': 58, 'title': 'CEO & Director', 'yearBorn': 1965, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.39
priceToSalesTrailing12Months§65.673325
currency§GBp
forwardEps§-6.38
exchange§LSE
quoteType§EQUITY
shortName§DESTINY PHARMA PLC ORD GBP0.01
longName§Destiny Pharma plc
firstTradeDateEpochUtc§1504508400
timeZoneFullName§Europe/London
timeZoneShortName§GMT
uuid§d77c1cd8-830c-3b33-8dfe-a60afade255b
messageBoardId§finmb_140099
targetHighPrice§285.0
targetLowPrice§65.0
targetMeanPrice§175.0
targetMedianPrice§175.0
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§2
quickRatio§9.322
grossMargins§1.0
ebitdaMargins§0.0
trailingPegRatio§None
